Assenagon Asset Management S.A. Gritstone Bio, Inc. Transaction History

Assenagon Asset Management S.A.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 06, 2023	SELL	$1.19 - $2.26 $453,426 - $861,130	-381,031 Reduced 30.52%	867,233 $1.49 Million
Q2 2023 Jul 25, 2023	SELL	$1.66 - $3.03 $481,572 - $879,015	-290,104 Reduced 18.86%	1,248,264 $2.43 Million
Q1 2023 Apr 18, 2023	SELL	$2.13 - $3.74 $867,617 - $1.52 Million	-407,332 Reduced 20.93%	1,538,368 $4.28 Million
Q4 2022 Jan 12, 2023	BUY	$2.17 - $3.92 $2.56 Million - $4.63 Million	1,181,630 Added 154.65%	1,945,700 $6.71 Million
Q3 2022 Oct 27, 2022	SELL	$2.46 - $4.75 $559,408 - $1.08 Million	-227,402 Reduced 22.94%	764,070 $1.96 Million
Q2 2022 Jul 27, 2022	BUY	$1.77 - $4.34 $1.75 Million - $4.3 Million	991,472 New	991,472 $2.4 Million

35.4M

395K

132K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

Stay updated on Assenagon Asset Management S.A. with notifications on news.